Skip to main content
European Commission logo
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-05-14

Identification of tumor-associated peptides presented by hla molecules from colon carcinoma cells

Objective



Stimulation or adoptive-transfer of tumor-specific T cells are, at present promising new lines in cancer immunotherapy. For melanomas, tumor-selective peptides presented by HLA-molecules to cytotoxic T cells (CTL) have been identified, first clinical trials being underway. For many other tumors including colorectalcarcinomas, relevant information is not yet available, although candidate antigens for tumor-specific immunity are known, including mutated-RAS. The objective of this proposal is to definitely identify HLA-class-one presented peptides of mutated-RAS and other tumor-associated proteins (ex: p53 CEA) by a purely biochemical approach. Large number of colorectal-carcinoma cells will be produced, either by in vitro culture or by expansion in nude mice of cell lines already established at INSERM U395. HLA-molecules will be precipitated and associated peptides will be extracted using procedures well established in Dr. Rammensee's group. Resulting peptide mixtures will be screened by mass-spectrometry for peptides conform with those predicted based on the protein sequence of the candidate antigens and allele-specific HLA motifs that have been determined in Dr. Rammensee's laboratory. Results are expected to give the basis for experimental immunotherapy of colorectal-carcinomas, using peptide specific CTL.

Call for proposal

Data not available

Coordinator

Eberhard-Karls-Universität Tübingen
EU contribution
No data
Address
7,Wilhelmstrasse
72074 Tübingen
Germany

See on map

Total cost
No data

Participants (1)